INTRODUCTION
The standard treatment for rectal adenocarcinoma has changed over time. In 1982, Heald et al introduced the concept of total mesorectal excision (TME), but this was adopted as standard treatment only during the nineties. In 1990 the Consensus Panel of the National Institutes of Health from the USA recommended adjuvant chemoradiation (CRT) as the standard of care for stage II and III rectal cancer [1] . In 2004 this standard was changed to neoadjuvant CRT for J Gastrointestin Liver Dis, June 2014 Vol. 23 No 2: 171-178 locally advanced rectal cancer (LARC: cT3/cT4&N0/N+, cT2N+) following the results of the CAO/ARO/AIO Rectal Cancer Trial [2] . e most important advantage of neoadjuvant CRT is a decreased local relapse rate when compared to surgery alone or surgery plus adjuvant CRT. is e ect is due to the higher rate of (true-) R0 resections (microscopically clear resection margins) and partial or complete response of nodal or extranodal pelvic metastases. Neoadjuvant CRT also yields an increased rate of sphincter preserving surgery. Furthermore, compared with surgery and adjuvant CRT there is less combined toxicity of neoadjuvant CRT plus surgery.
In clinically complete responders a er neoadjuvant CRT an experimental approach is the follow-up with salvage surgery if necessary. Radiotherapy doses of 45 to 50 Gy with concomitant chemotherapy yield a clinical complete response (CCR) rate between 10.4% [3] and 27% [4] . e pathological complete response (PCR) can be higher, up to 35.1% [4] [5] [6] [7] . Brachytherapy or orthovoltage boost approaches can yield a CCR of about 81% in selected patients [8, 9] . e current prospective observational study was performed with the aim to find prognostic factors related to downstaging and complete response (clinical or pathological) when an intensi ed neoadjuvant schedule is used, consisting of induction chemotherapy and concomitant CRT with a dose of 50 Gy in 25 fractions to all macroscopic lesions (tumor and suspicious lymph nodes).
METHODS
We have prospectively included in our observational study in a set timeframe between March 2011 and October 2013, 88 patients with LARC (including patients with metastases con ned to a single organ or site) who received neoadjuvant treatment at the Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj.
Inclusion criteria were: biopsy proven adenocarcinoma of the rectum with a distal tumor border within 15 cm from the anal verge (AV) as measured with digital rectal examination, rigid proctoscopy and/or MRI; extension to the sigmoid was allowed; age between 18-80 years; clinical stage II (T3-4, N0), stage III (any T, N1-2), stage IV A (any T, any N, M1a, i.e. metastases con ned to a single organ or site); Eastern Collaborative Oncology Group performance status (ECOG PS) of 0 or 1; Hb > 9 g/dl, neutrophil count >1500/ µl, platelets > 100,000/µl; proper liver function and indication of neoadjuvant treatment.
Exclusion criteria were: recurrent rectal adenocarcinoma; multiple colon adenocarcinomas; prior pelvic irradiation.
Staging, evaluation and treatment protocol
Local and lymph node staging was performed by MRI and/or endorectal ultrasound (EUS). In addition, patients underwent a full colonoscopy (if there was no stenosis at the level of the rectal tumor), CT examination with iodinated contrast of the abdomen and pelvis, a chest x-ray or chest CT examination. Carcinoembryonic antigen (CEA) and CA 19-9 antigen were recommended to be measured in serum before any treatment. 2 ) on day 1 and 2. Chemotherapy with uoropyrimidines is contraindicated when there is signi cant cardiac disease or the le ventricular ejection fraction is lower than 50%. In these cases Irinotecan can be used with monitoring of the heart rate and blood pressure. Dose reduction of uoropyrimidines and Oxaliplatin is applied when creatinine clearance is <30 ml/min.
Radiotherapy is administered according to an institutionally approved protocol. It is delivered with a conformal technique, using 15 MV beams; combination with a 6MV beam could be used to compensate low close-to-surface dose. e prescription dose is 46 Gy in 23 fractions (31 days) to the primary PTV (PTV1, planning treatment volume 1) and 50 Gy in 25 fractions (33 days) to the secondary PTV (PTV2). PTV1 includes the whole rectum (except the sphincter in middle or upper tumors), the whole mesorectum, the internal iliac lymph nodes and the obturatory lymph nodes in tumors within 10 cm from the AV. PTV2 includes the tumor with a 2 cm cranial and caudal margin, the whole mesorectum and all suspicious lymph nodes. e concomitant chemotherapy is Capecitabine 1650 mg/m 2 /day, every day with radiotherapy (5 days/week). After neoadjuvant treatment patients are referred for surgical intervention, which is recommended to be performed at 6-8 weeks a er the last radiotherapy fraction. In a subset of patients who refuse to undergo surgery, tumor response is assessed by MRI or EUS combined with rectoscopy at 6-8 weeks from the end of CRT. e de nition of a CCR is: (1) no residual tumor or only residual brosis on MRI or EUS; (2) no suspicious lymph nodes on MRI or EUS; (3) no residual tumor on rectoscopy and digital rectal examination.
Data analysis
e down-staging data was analyzed by comparison of the initial clinical stage with the one obtained on the surgical specimen or on clinical restaging, if patients did not undergo surgery. Each staging component (T, N) was analyzed separately.
For prognostic factors, T down-staging was analyzed instead of combined T and N down-staging, since MRI and US evaluation of T stage is more reliable. Furthermore we analyzed the tumor response grade (TRG) for radically operated patients.
For prognostic factor analysis of complete response we combined the numbers of pathological and clinical complete responders (since there were patients who refused surgery J Gastrointestin Liver Dis, June 2014 Vol. 23 No 2: 171-178 upon achieving CCR). e analysis of CCR in all patients was not one of the goals of this study.
Staging and TRG measurement were performed according to the American Joint Committee on Cancer (AJCC) Cancer Staging, 7th edition [10] . Acute side-effects were graded according to the Common Terminology Criteria for Adverse Events version 4 (CTC4.0).
ROC curves and chi square test with Yates correction were used for analysis of the prognostic factors for T down-staging and complete response. The cut-off values for numerical variables were chosen based on the minimal distance of the ROC curve from point (0,1). Con dence intervals were estimated at a threshold of 95%. Statistical signi cance was set at p≤0.05. FileMaker was used for data entry and Excel for data analysis.
e Kaplan-Meier method with log-rank test was used for survival analysis.
Informed consent was acquired for all patients regarding the use of radiation therapy, chemotherapy, surgery, clinical tests, analysis and publication of anonymized medical information. e treatment protocol was approved by the 
RESULTS
A total of 88 patients met initially all eligibility criteria and were enrolled in this observational study. From the 88 patients, 2 did not nish CRT: one developed G3 diarrhea and decided to interrupt the treatment and one patient died in the course of CRT due to venous thromboembolism. ese two patients were not included in the analyses (Table I) .
Seventy-one (82.6%) patients received the standardized 50 Gy in 25 fractions to the PTV2. Protocol deviation was encountered in 15 patients (17.4%): 6 patients received a dose between 44-48 Gy, 3 patients 50.4 Gy in 28 fractions (1.8 Gy/ fraction) and 6 patients 52-54 Gy in 26-27 fractions.
From the 86 patients, 79 patients received induction chemotherapy (91.9%) and 54 patients (62.8%) received Sixty-eight patients (79.1%) underwent radical surgery and 3 patients palliative surgery. Five patients (5.8%) were considered inoperable on post-CRT imaging. Ten patients (11.6%) refused radical surgery. From these, 2 patients had CCR and 8 had residual disease. From the patients with residual disease 3 had no down-staging on MRI and 5 refused any re-staging.
From the 68 patients who underwent radical surgery, 34 (50 %) had anterior resection, 32 (48.5%) abdomino-perineal resection, one pelvic exenteration and one endoscopic resection.
Seven cases presented ypT0 stage on the nal pathology from 68 patients who underwent radical surgery (10.3%) and from these 6 were ypN0. Only one case of the 7 ypT0 cases had ypN1a, presenting a metastasis in a single lymph node, but with extensive necrosis. is case was considered for further analyses as having PCR. If we combine the 7 ypT0N0 (PCR) cases with the 2 CCR cases, 9 patients out of 81 evaluable patients presented complete response (11.1%).
Overall, severe acute toxicity was low: G3 digestive toxicity in 11.7% of cases, G3 and G4 hematologic toxicity in 2.4%, G3 radiation dermatitis in 5.8% and G3 peripheral sensory neuropathy in 10.8%. (Table II) Down-staging analysis When analyzing the down-staging of the primary tumor we compared the initial clinical T stage and the pathological T stage. Furthermore, in 5 of the 10 patients who refused surgery, we were able to obtain clinical restaging: 2 of them had CCR and 3 had stable T stage. We also included in the analysis the 5 inoperable patients a er CRT.
us we analyzed the T down-staging for 68 radically and 3 palliatively operated patients, including the 2 patients with CCR, the 5 patients with inoperable disease and the 3 patients who refused surgery but had stable disease.
In these 81 patients T down-staging was present in 40 (49.4%). A stable T stage was found in 37 (45.7%) and a higher T stage in 4 (4.9%). (Individual T down-staging is shown in Table III) .
We analyzed the TRG for the 68 radically operated patients. Seven patients (10.3%) had TRG=0 (PCR), 12 patients (17.6%) moderate response (TRG=1), 29 patients (42.6%) minimal response (TRG=2) and 20 patients (29.4%) poor response (TRG=3). Tumor down-staging and TRG were correlated (p=0.05).
For analysis of N down-staging we compared the initial cN and the nal pN stage for the 68 radically operated patients, including the 2 cases with CCR and the 3 patients who refused surgery but underwent clinical restaging. us 49/73 (67.1%) patients had a smaller yN stage; 10 patients (13.7%) had N0 both on the initial and post-CRT staging; 11 patients a stable N stage (15.1%) and 3 patients (4.4%) a higher N stage.
Using ROC curve analysis and chi square test for potential prognostic factors for T down-staging we found statistical signi cance for: age older than 57 years, cN0 stage versus cN1-2, distance of the lower pole of the tumor from the AV > 5 cm, initial CEA < 6.2 ng/ml, higher number of Oxaliplatin containing chemotherapy cycles and a protraction of radiotherapy of more than 35 days (Table IV) . All these were independent factors. Other factors analyzed which did not reach statistical signi cance for T down-staging were: gender, cT stage and cM stage, tumor grade, initial tumor length, involvement of the sigmoid, macroscopic subtype, invasion of the perirectal fascia on MRI and number of non-Oxaliplatin chemotherapy cycles. e statistically signi cant independent prognostic factors for complete response were cT2 stage versus cT3-T4, tumor size ≤3.5 cm and tumor distance of >5 cm from the AV (Table V) . (Figs. 1 and 2) . A value of CEA > 6 ng/ml was inversely correlated with survival (p=0.03).
Higher values of CA 19-9 were found in G3 tumors. When a cuto of 80 U/ml was chosen, 75% of G3 tumors had a CA 19-9 > 80 U/ml, versus only 10.5% of G1/2 tumors (p=0.03). G3 frequency was independent from tumor stage (in stage II there were 10% G3 tumors, in stage III 9.09% and in stage IV 12.5%, p=ns).
Relapse and survival e median follow-up from diagnosis was 16.7 months (3.8-33.4). From the 68 patients who underwent radical surgery only 1 presented local plus nodal relapse and 3 presented metastases. Fourteen deaths were recorded in the followup (14/86, 16.3%), 11 caused by the rectal cancer and 3 by cardiovascular disease.
e overall survival at 18 months was 86% for M0 cases and 57% for M1a (p<0.01).
DISCUSSION
The rate of T down-staging (49.4%) was similar to what other teams described when studying CRT including Oxaliplatin, i.e., around 43-58% [11, 12] . e rate of complete responses (11.1%) was similar with the reported 10.4-25.6% in studies including several stages [13] , although on the lower end of the range, probably due to a large number of advanced cases (cT3N2 35/81 or 43.2%; cT4b 19/81 or 23.5%).
Adjuvant chemotherapy containing Oxaliplatin is a recognized option as an adjuvant treatment for T3N0, any-T and N+, and T4 and any-N rectal adenocarcinoma [14] . Oxaliplatin chemotherapy during radiotherapy was tested in several clinical trials. Four phase III clinical trials added weekly Oxaliplatin (50 or 60 mg/m2) in one arm of radiotherapy plus concurrent 5FU or Capecitabine (STAR-01 [5] , ACCORD12/0405 Prodige 2 [15] , NSABP R-04 [16] , CAO/ ARO/AIO-04 [17] ).
e STAR-01 and NSABP R-04 clinical trials could not demonstrate an increase in the PCR rate, but in the STAR-01 there was a decrease in the rate of intra-abdominal metastases (ypM1 2.9% for 5FU vs. 0.5% for Oxaliplatin; p=0.014).
The ACCORD clinical trial intensified both the chemotherapy schedule by adding Oxaliplatin and the RT dose, by increasing the total dose from 45 Gy/25 fr to 50 Gy/25 fr (and increasing the dose per fraction from 1.8 to 2 Gy). ere was an increase in the PCR (when a cuto of 2 mm was used to de ne it): 9.9% with Capecitabine plus 45 Gy and 19.3% with CAPOX plus 50 Gy (p=0.02).
e CAO/ARO/AIO-04 demonstrated that PCR could be increased by concomitant Oxaliplatin, although the di erence was small (17% vs. 13%, p=0.038).
GCR-3 was a phase II randomized clinical trial where Oxaliplatin 50 mg/once every week was administered with radiotherapy in both arms; additionally 4 cycles of CAPOX were included, in arm A as adjuvant, in arm B as neoadjuvant treatment [11] . Down-staging and PCR were similar, and when analyzing the 3-year results the authors stated: "although not powered to draw any comparative conclusions, induction chemotherapy … yields similar three-year outcomes as standard strategy. " As a bene t for the neoadjuvant approach there was less acute toxicity and better compliance than with the adjuvant chemotherapy [11] .
We studied Oxaliplatin used as the induction chemotherapy followed by CRT without concomitant Oxaliplatin. Induction chemotherapy for LARC is an optional treatment in the protocol for rectal adenocarcinoma of the Institute of Oncology Prof. Dr. Ion Chiricuta. Although it is not a standard option internationally, it was adopted for potential bene ts such as better compliance, early treatment of subclinical metastases and possibly better down-staging.
In our observational study, down-staging was more frequent with a higher number of Oxaliplatin containing chemotherapy cycles, although a cut-o number of cycles could not be established. Similar results have been described by Calvo et al [18] . They compared the down-staging and PCR rate between two consecutive groups of patients. One group comprised 114 patients and received only concomitant CRT with oral A randomized clinical trial with induction chemotherapy before CRT might further clarify the role of Oxaliplatin in the neoadjuvant treatment of rectal adenocarcinoma, especially regarding reduction of the rate of metastases. e most intriguing nding was that a length of radiotherapy of more than 35 days in uenced down-staging bene cially. is aspect might be somewhat similar to when a longer wait period (>6-8 weeks) is used from the end of CRT until the moment of surgery [19] . Hypotheses for the phenomenon observed by us are: better revascularization, tumor reorganization and/or higher chance to have mitotic cancer cells when treatment is delivered (synchronization). Nonetheless, the protraction of treatment or increase of wait before surgery might negatively in uence the rate of local relapses and metastases due to relatively radioresistant clones and accelerated repopulation.
CEA was described recently by Yeo et al as one of the important factors predicting down-staging. e ypT0-2 rate was 57.1% when CEA was ≤5 ng/ml vs. 27.4% when CEA was >5 ng/ml [20] CA 19-9 is becoming an important marker in colorectal cancer, although it is not included yet in standard protocols. It has been shown since the nineties that it is an independent prognostic factor [21] and is useful in metastatic disease [22] ; recently its value has been demonstrated for follow-up [23] . Increased CA 19-9 has been correlated with high CEA, lymph node metastasis, right colon tumors, large tumor size and peritoneal seeding [24] . We have shown that CA 19-9 is more frequently increased in G3 tumors, independently of the (clinically established) stage.
e limits of our study are the relatively small number of patients, a certain degree of heterogeneity of the patient groups and the fact that it was only an observational study and not a randomized clinical trial.
CONCLUSIONS
Neoadjuvant chemoradiation with induction chemotherapy containing Oxaliplatin produces important down-staging in rectal adenocarcinoma and results in a high rate of sphincter preserving surgery. ere are several prognostic factors for T down-staging and complete response. Based on our results, we consider that a randomized clinical trial in LARC with Oxaliplatin induction chemotherapy in one arm to compare the down-staging, complete response, local relapse and metastasis rate should be performed.
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